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  i 
FOREWORD 
While this thesis is the culmination of a few years, it is based and adds upon the work of many 
that have dared to tread into the unknown. A path not studded with eureka moments, rather 
many pondering nights and slaving days to reveal the truths behind these devastating diseases. 
My journey is not much different from that of my predecessors; its start begins with a curious 
mind and barely any research skills whatsoever. Having to learn everything, including the 
somewhat basic ability to pipette, the patience of the people around me catapulted that process 
tremendously. It was the fun-loving atmosphere that kept that laborious work going especially 
when the bouts of work got overwhelmingly tedious. The one-team mentality shared among all 
our group members cemented that environment into one of the most effective and cohesive 
groups within our department. The members were hand picked and within a field with so many 
socially awkward disciples, Ángel made sure that none passed his iron curtain of sanity.  
Science driven by direct irrefutable empirical evidence was the pursuit we were after, however 
being bombarded with expert opinions guided by scant research and a dogmatic perspective was 
more the reality. This was evident since we dared to defy Alzheimer’s research by publishing 
without emphasizing the canonical amyloid beta, thus being honored with the Oscar of most 
rejections for a single paper being 12. This continued with our successive paper, still struggling 
with its acceptance 20 months from its first submission. Of course you might say we are biased 
and possess the mentality that the world is against us. I tell you when you write a second 
response to the one reviewer (the other two were happy with our second modified manuscript) 
who persistently rejects not only your results but also that of many highlighted in a rebuttal letter 
spanning 8 pages and 37 references, only to be further coerced by an editor to reply in a more 
polite and less combative manner and stating that the acceptance lies in his/her hand, after which 
the reviewer stubbornly denies the widespread existence of a protein in the brain, then you can’t 
possibly think science is based on empirical evidence.  
Yet there is much hope in the field with many audaciously formulating new threads of thought 
that may very well lead to the better understanding of Alzheimer’s disease and ultimately its 
treatment. To them I salute and acknowledge their uphill march not only in challenging the 
status quo, but their extensive struggle in achieving great quality science.   
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ABSTRACT 
Cholesterol is constantly attributed to neurodegenerative diseases including Alzheimer’s disease 
(AD). This is due to the association of high blood cholesterol and the consequences of 
cholesterol metabolism in these conditions. However the brain isolates itself from the peripheral 
cholesterol with the use of its impervious barrier, therefore how does cholesterol influence the 
brain?  
Converted into the oxidized form known as 27-hydroxycholesterol (27-OH), extracerebral 
cholesterol is able to circumvent this blood brain barrier and enter the brain’s refuge. Some 
studies point to the effect of this oxysterol on brain cells, indicating that this metabolite is more 
than a cholesterol intermediate. Herein, we dissect the role this cholesterol metabolite undertakes 
in the brain both in vitro and in vivo, while probing its influence on neurodegenerative diseases.  
In Paper I we elucidated the levels of 27-OH in both the cerebrospinal fluid (CSF) and plasma 
of mild cognitively impaired (MCI) and AD patients. In addition to correlating it to AD markers, 
we further investigated its relationship with the angiotensin-converting enzyme (ACE), which 
was increased in AD as previously described. Delving deeper uncovered 27-OH had more of a 
causal link than a mere correlation with the renin-angiotensin system (RAS) in the brain 
highlighted in Paper I and Paper II. This system, apart from being independent from the renal 
system, is involved in many processes in the brain including learning and memory. The 
repercussions of 27-OH on the brain RAS was further investigated in vivo in Paper II, in mice 
lacking the ability to produce 27-OH, and in humans. Furthermore, the effects of 27-OH were 
also observed in mice fed a high-fat diet, a connection that is further investigated in all the papers 
within this thesis. These results draw to attention the relationship between plasma cholesterol, 
hypertension and neurodegeneration.  
In addition to affecting the spatial memory of mice, 27-OH reduced the levels of glucose uptake 
in their brains. Emphasized in Paper III, the mechanistic link between 27-OH and glucose 
metabolism was examined, explicating several therapeutic targets. The biomarker suitability of 
27-OH was tested in a small proof of concept study utilizing 18F- fluorodeoxyglucose positron 
emission tomography (18F-FDG PET). Results illustrated a negative correlation, thus having 
higher levels of 27-OH in the CSF is associated with lower glucose uptake levels in the brain of 
individuals with ramifications on memory.  
Inflammation is an important part of AD and is thought to occur very early in the disease 
progression. Moreover, peripherally 27-OH plays a part in mediating atherosclerosis via its 
proinflammatory actions.  To this end, we hypothesized that 27-OH may have similar actions in 
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the brain and the resulting data is presented in Paper IV. 27-OH increased the levels of the 
inflammatory mediator S100A8 in addition to its receptor, Receptor for Advanced Glycation 
Endproduct (RAGE) and the downstream β-secretase 1 (BACE1) observed in several mice 
models. S100A8 was previously described by us to be increased in the brains of AD mice models 
and may accumulate even before amyloid plaque formation. This study therefore accentuates the 
function of 27-OH in propagating inflammation in the brain, a function recognized peripherally. 
Neurodegenerative diseases such as AD are debilitating conditions affecting the lives of millions; 
however to this date the causes of these overwhelming disorders remains unclear. While the 
levels of CSF 27-OH are likely to be increased in many AD patients, little is known as to the 
ramifications of this increase. Herein, we try to bridge this gap and propose several mechanistic 
links between blood cholesterol and neurodegenerative diseases while underscoring several 
plausible therapeutic targets, in an attempt to further empower our fight against AD.  
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1 INTRODUCTION 
1.1 NEURODEGENERATION 
The definition of neurodegeneration, as you would have already formulated in your mind by 
now, is roughly the degeneration or loss of function of neurons. While this classification appears 
to be obvious, the reality is much more complicated. Conditions such as brain tumors, epilepsy 
and multiple sclerosis, despite the involvement of neuronal damage, are generally not considered 
neurodegenerative diseases1. Therefore when neurodegenerative diseases are mentioned, the 
more commonly discussed are diseases such as Alzheimer’s disease (AD), Parkinson disease 
(PD) and Huntington disease. According to the EU Joint Programme-Neurodegenerative 
Disease Research (JPND), the largest research initiative tackling neurodegeneration, 
neurodegenerative disease is a term that encompasses a range of diseases resulting in incurable 
and debilitating states from progressive neuronal death, with a focus on movement or memory 
disorders2. Neurodegenerative diseases are approximated to be in the hundreds, and their 
classification is constantly challenged by the superimposed depiction of the many diseases both 
clinically and pathologically. While I will not delve into attempting to classify and discuss these 
myriad diseases, Przedborski et al. made a brilliant effort at just that3. This thesis will focus more 
on the memory aspect of neurodegenerative diseases, of which AD is the most prevalent form.  
1.2 DEMENTIA  
Dementia in itself is also an umbrella term for a spectrum of diseases that afflict a person’s 
memory and lead to cognitive impairment. Even though memory seems to be the major 
complaint, other cognitive domains such as language and orientation must be impaired for a 
diagnosis to be given. The progression of these symptoms eventually affects an individual’s 
ability to cope with their daily living and thus cripple their independence. The prevalence of 
dementia subtypes include 32% vascular dementia, 8% Lewy body dementia, 3% PD associated 
dementia, 3% Frontal Temporal dementia and the lion share belonging to AD, contributing to 
41% with many speculating it to be up to 70%4,5. It is important to note that this demarcation 
between the different dementia subtypes is not strict, with mixed pathologies being more 
frequent than pure6. 
1.3 ALZHEIMER’S DISEASE 
Being characterized by the presence of neurofibrillary tau tangles and amyloid plaques, the loss of 
synapses and neurons in cortical areas are also important features of the disease. While the cause 
is still unknown, speculations regarding the etiology are monopolized by the amyloid cascade 
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hypothesis7, which states that the disease is driven by the deposition of amyloid beta (Aβ). Even 
though this hypothesis is partly generated from the genetic data implicating mutations in the 
Amyloid Precursor Protein (APP), several other genetic risk factors have been determined and 
are summarized in Fig 1. These genes are considered more common within the population, 
although their risk in producing the disease dwarfs in comparison to the inevitability of the 
deterministic APP and presenilin (PS) 1 and 2 mutations8, known to ultimately cause the early-
onset forms of AD (eoAD).  
 
 
Fig. 1. GWAS determined genes plotted with regards to its relative risk to AD and its frequency in the population. 
Reproduced from Hardy, J. et al. Pathways to Alzheimer's disease. Journal of Internal Medicine 275, 296-303, 
doi:10.1111/joim.12192 (2014)8 under the Creative Commons license. 
These deterministic genes have however been erroneously used experimentally to model the 
sporadic forms9, even though genome-wide association study (GWAS) has unveiled that the 
frequent genes point towards several other mechanisms such as endosome vesicle recycling, 
cholesterol and the immune system10, which have been extensively investigated with regards to 
their mechanistic contribution to the disease. The effects of these systems have been 
superimposed onto the amyloid cascade, by investigating them in both in vitro and in vivo eoAD 
disease models thus the interpretation of this data has to be done with caution when translating 
the results into sporadic AD. It is equally important to highlight that cognitively normal 
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individuals exhibiting progressive AD pathology do not develop dementia6,11. This incongruence 
has contributed to the current status in therapeutic targeting of AD, with the vast majority of 
pharmacological clinic trials being unsuccessful12. This predicament accentuates the need for the 
adequate modeling of the sporadic forms of AD.    
1.4 RISK FACTORS  
Age is without a doubt the most important risk factor for AD, however so far the second most 
influential factor is the genetic ε4 allele of the Apolipoprotein E (ApoE). This allele not only 
increased the risk for AD threefold and fifteen times when homozygous, it also reduces the 
onset of the disease whether the sporadic form or eoAD13. Only 14% of the global population 
express the ε4 allele, with the vast majority carrying the ε3 allele14. Furthermore, studies have 
shown that in combination with APOEε4, environmental risk factors augmented not only the 
risk but also the severity of the disease15,16. These included chronic diseases such as diabetes, 
elevated midlife blood cholesterol levels, depression and hypertension in addition to lifestyle 
factors such as alcohol consumption, physical and cognitive activity17. Some of these, identified 
as modifiable risk factors had a combined attributable risk of half the worldwide cases of AD18. 
The targeting of these factors, exhibited in a recent multimodal clinical trial with at-risk elderly 
population19, revealed a 25-150% improvement in cognitive outcome in comparison to the 
control group. These findings emphasize the importance of these risk factors in AD or indeed 
cognitive decline. Far from being an extensive review, the following section encapsulates a short 
account of some of these modifiable factors. 
1.4.1 Hypertension 
The relationship between hypertension and AD or dementia has been vastly covered with many 
considering it a risk factor for all types of dementia20. Although inconsistencies exist between the 
various studies, age appeared to be the contradicting factor21,22.  Late life hypertension was not 
associated with the risk for AD or dementia; on the contrary hypotension, as well as patients 
taking antihypertensive medication have been associated to the risk for AD20.  Furthermore, the 
effect of having high blood pressure in midlife was assessed in several longitudinal studies, which 
asserted that cognition was consistently negatively influenced22. The use of anti-hypertensive 
drugs reduced the risk of dementia23,24, though this was not observed in a recent meta-analysis 
conducted on several randomized control trials25. Nonetheless they noticed significantly less 
cognitive decline in the treated group.  
Explaining the mechanistic link between hypertension and dementia is still controversial, 
proposed mechanisms include atherosclerotic lesions and/or hemodynamic insufficiency22. 
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Blood pressure is regulated by complex mechanisms, most importantly by the systemic 
endocrinal renin angiotensin system (RAS). The injection of angiotensin (Ang) II 
intracerebroventricularly caused brain-orchestrated hypertension and ultimately led to the belief 
that RAS is present centrally26. This brain RAS, entirely autonomous from the peripheral system, 
is known to regulate hypertension and is currently targeted for the control of peripheral blood 
pressure27. Apart from its regulatory power over blood pressure, central RAS modulates cerebral 
blood flow, the autonomic system and more importantly within the context of this thesis, 
memory processing28. This central system is also presently recognized in several diseases 
involving the brain such as AD, stroke and depression29. One proposed interaction between 
central RAS and AD is based on the binding of ACE to Aβ1-42, and long-term treatment with 
ACE inhibitors increased the deposit of Aβ1-42 in old age AD mouse model. Furthermore, 
hypertension and memory impairment were seen in mice chronically infused with AngII30, 
whereas the use of an angiotensin receptor blocker reduced the Aβ-induced cognitive 
impairment in an AD mouse model31. Taken together, these data further implicates brain RAS 
with neurological diseases, though more studies are required to discover both the underlying 
basic mechanism and new therapeutic targets. 
1.4.2 Diabetes 
With several groups calling it diabetes type 3, AD has many features in common with the 
metabolic disease. Advanced AD patient brains revealed decreased levels of both insulin and 
its receptor despite the patients not having diabetes32. This is especially important as the 
signaling of insulin, shown to be impaired in AD, plays a crucial role in tau phosphorylation, 
the key protein in the development of neurofibrillary tangles present in several tauopathies33. 
Insulin signaling is also vital for the survival and function of both neurons and 
oligodendrocytes34. Moreover, streptozotocin (STZ) brain injections revealed AD 
neuropathological features including brain atrophy and increased immunoreactivity towards 
Aβ, in addition to higher tau mRNA levels in the STZ-injected rats35. Furthermore, the 
intranasal injection of insulin in a triple transgenic AD mouse restored insulin signaling, 
increased synaptic proteins and reduced Aβ1-40 levels
36, accentuating the role insulin signaling 
has in AD.  
An important feature of diabetes is hyperglycemia, however no data exists to suggest that 
excess glucose is present in AD brains, a critical point that would rebuke the diabetes type 3 
hypothesis37. On the other hand, evidence exists to link hypoglycemia to cognitive dysfunction, 
therefore supporting glucose hypometabolism as an important feature of AD38,39. AD-
associated glucose hypometabolism is thought to occur relatively early in the course of the 
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disease40. In fact, increasing the presence of glucose in the brain potentiates memory 
processing41. While dysfunctional insulin signaling, a complex cascade in itself, is not enough to 
explain the pathology observed in AD, glucose transporters (GLUT) have been shown to be 
implicated42.  
Several GLUTs are present in the brain including GLUT1, with two isoforms expressed in 
endothelial cells lining the blood brain barrier (BBB) and astrocytes, is mainly involved in 
mediating glucose into the brain43. GLUT3, the main neuronal transporter, is also present in 
glia and is expressed throughout the brain, exhibiting a higher affinity to glucose than both 
GLUT1 and GLUT444. A lingering misconception is that the insulin sensitive-GLUT4 is only 
expressed in the hippocampus, however this transporter is observed throughout the brain 
including the hypothalamus, motor cortex, piriform and entorhinal cortices, most neocortical 
areas, as well as in different nuclei of the limbic and motor systems, pituitary, olfactory bulb 
and basal ganglia45-50. Furthermore, the glucose transport capability of neurons (via GLUT3 
and GLUT4) surpasses that of astrocytic GLUT1, based on the kinetic characteristics and the 
cellular concentration of glucose in both neurons and glia51. This is consistent with the notion 
that synaptic connectivity and communication bears the largest demand for energy in the 
brain52.  
Not many studies have investigated GLUT4 in AD, though a recent study observed decreased 
levels in neurons treated with exogenous Aβ1-42
53. Although one could argue that glucose 
alterations are seen earlier than amyloid deposition, a recent study revealed that decreased 
levels of low-density lipoprotein receptor-related protein 1 (LRP1), implicated in the 
pathogenesis of AD, led to insulin resistance and GLUT4 reduction54. In AD, GLUT1 and 
GLUT3 are also decreased, suggesting that this reduction in GLUTs may possibly contribute 
to the observed reduction in glucose metabolism55.  This reduction not only correlates with the 
progression of AD, it could also contribute to diagnosis56. Remarkably, population-based 
studies have also observed the link between diabetes and AD, where some studies have 
correlated diabetes to an increased risk for AD by approximately 50%, independent of vascular 
dementia57.  
1.4.3 Hypercholesterolemia 
Cholesterol was first featured in dementia as a differential diagnostic marker between AD and 
multi-infarct dementia58. In the decades to follow, a plethora of epidemiological data correlated 
high cholesterol levels in the blood to the increased risk of AD59. A few studies have also shown 
a positive correlation of higher cholesterol with the risk for dementia in older individuals60,61. This 
was further strengthened by studies that affirmed the risk of AD with higher cholesterol was 
 
  5 
disease40. In fact, increasing the presence of glucose in the brain potentiates memory 
processing41. While dysfunctional insulin signaling, a complex cascade in itself, is not enough to 
explain the pathology observed in AD, glucose transporters (GLUT) have been shown to be 
implicated42.  
Several GLUTs are present in the brain including GLUT1, with two isoforms expressed in 
endothelial cells lining the blood brain barrier (BBB) and astrocytes, is mainly involved in 
mediating glucose into the brain43. GLUT3, the main neuronal transporter, is also present in 
glia and is expressed throughout the brain, exhibiting a higher affinity to glucose than both 
GLUT1 and GLUT444. A lingering misconception is that the insulin sensitive-GLUT4 is only 
expressed in the hippocampus, however this transporter is observed throughout the brain 
including the hypothalamus, motor cortex, piriform and entorhinal cortices, most neocortical 
areas, as well as in different nuclei of the limbic and motor systems, pituitary, olfactory bulb 
and basal ganglia45-50. Furthermore, the glucose transport capability of neurons (via GLUT3 
and GLUT4) surpasses that of astrocytic GLUT1, based on the kinetic characteristics and the 
cellular concentration of glucose in both neurons and glia51. This is consistent with the notion 
that synaptic connectivity and communication bears the largest demand for energy in the 
brain52.  
Not many studies have investigated GLUT4 in AD, though a recent study observed decreased 
levels in neurons treated with exogenous Aβ1-42
53. Although one could argue that glucose 
alterations are seen earlier than amyloid deposition, a recent study revealed that decreased 
levels of low-density lipoprotein receptor-related protein 1 (LRP1), implicated in the 
pathogenesis of AD, led to insulin resistance and GLUT4 reduction54. In AD, GLUT1 and 
GLUT3 are also decreased, suggesting that this reduction in GLUTs may possibly contribute 
to the observed reduction in glucose metabolism55.  This reduction not only correlates with the 
progression of AD, it could also contribute to diagnosis56. Remarkably, population-based 
studies have also observed the link between diabetes and AD, where some studies have 
correlated diabetes to an increased risk for AD by approximately 50%, independent of vascular 
dementia57.  
1.4.3 Hypercholesterolemia 
Cholesterol was first featured in dementia as a differential diagnostic marker between AD and 
multi-infarct dementia58. In the decades to follow, a plethora of epidemiological data correlated 
high cholesterol levels in the blood to the increased risk of AD59. A few studies have also shown 
a positive correlation of higher cholesterol with the risk for dementia in older individuals60,61. This 
was further strengthened by studies that affirmed the risk of AD with higher cholesterol was 
  6 
most significant in mid-life or more recently early AD62-64. This relationship between blood 
cholesterol and AD was confirmed in vivo where feeding a high fat diet to animals led to AD 
neuropathological features65,66. Furthermore, the cholesterol transporter APOEε4, as previously 
mentioned, increased the risk for AD13 and is associated with increased low-density lipoprotein 
(LDL) cholesterol in the blood67. The metabolic syndrome, composed of high blood pressure, 
blood glucose and abnormal blood cholesterol levels, was also seen to increase the risk of AD 
among other diseases68. Nonetheless, these conditions are also considered to be modifiable risk 
factors for dementia, and targeting these factors is now considered part of the prevention of 
AD5, hence solidifying the contention that peripheral cholesterol may have a possible role in 
mediating AD. Despite all these evidence pointing to the importance of blood cholesterol in AD, 
cholesterol does not cross the BBB, therefore how does it impose its action on the brain? This 
will be further discussed in the next section.   
1.5 CHOLESTEROL AND THE BRAIN; AN INTIMATE AND COMPLEX 
RELATIONSHIP 
The brain is isolated from the rest of the body by the function of the BBB. This barrier, with its 
tight junctions, prevents many substances present in the blood from entering the brain’s refuge, 
including cholesterol. Therefore, how does the brain, which contains 25% of the body’s 
cholesterol69, obtain its cholesterol? All the cholesterol in the brain is thus produced locally, with 
synthesis being considerably high during development and substantially reduced during 
adulthood70,71. Interestingly, this reduction is thought to increase the half-life of brain cholesterol 
to span five years72.  
Cholesterol is synthesized from acetyl-CoA through an arduous and energy-taxing series of 
conversions that takes place mainly in oligodendrocytes and astrocytes73,74. Although neurons are 
also capable of producing cholesterol, they postnatally mainly rely on astrocytes for its 
cholesterol, while oligodendrocytes provide myelin its cholesterol during axon coating73. It is 
worth mentioning that brain cholesterol is predominantly unesterified and the primary 
component of both myelin and the plasma membranes lining neurons and glia74. Astrocytes are 
able to provide neurons with cholesterol not only due to their cholesterol synthesizing capability 
but also via their production of ApoE, the cholesterol transporter75. ApoE is secreted by 
astrocytes together with cholesterol, which allows receptor-mediated uptake of cholesterol 
containing-lipoproteins by neurons. This also allows cholesterol homeostasis within the brain 
through the excretion of excess cholesterol, achieved with the release of 1-2 mg of ApoE-bound 
cholesterol into the CSF per day76. More significant is the elimination by conversion to 24S-
hydroxycholesterol (24S-OH), estimated to be 6-7 mg/day, making it the major cholesterol 
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elimination pathway72. This is evident as 24S-OH, mainly produced in the brain, is able to 
traverse the BBB with a net outflux observed72.  
Cholesterol is vitally important for the normal functioning of the brain. The structure of the 
brain is determined by cholesterol, including neuronal membranes and the myelin sheath that 
enables its conductive properties74. Cholesterol impacts neurotransmission through its influence 
on the function and release of synaptic vesicles, which is dependent on the cholesterol content77. 
It was observed that altering the amount of cholesterol postsynaptically caused the loss of 
dendritic spines and synapses, therefore undermining neurotransmission78. Moreover, the 
importance of cholesterol in the brain is additionally evident from the various diseases impacting 
cholesterol synthesis and causing neurological deficits. As discussed in the previous section, the 
relationship between blood cholesterol and AD has led to several theories on the influence 
cholesterol in the brain can have on the development of AD, which have been summarized in 
Fig. 2. This is in addition to the evidence that reducing cholesterol in membranes favored alpha-
cleavage of APP and reduced the formation of Aβ, thereby motivating the use of statins in the 
treatment of AD79,80. While clinical trials with statins have only yielded inconsistent results81, and 
that the cholesterol content in the brain of AD patients is seemingly low, it remains a puzzle how 
targeting cholesterol in the brain might help prevent AD.  
                            
Fig. 2. The different mechanisms of how cholesterol influences APP processing. Reproduced from Grimm, M. O., 
Rothhaar, T. L. & Hartmann, T. The role of APP proteolytic processing in lipid metabolism. Exp Brain Res 217, 365-
375, doi:10.1007/s00221-011-2975-6 (2012)82 under the Creative Commons license. 
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1.6 THE CHOLESTEROL METABOLITE 27-HYDROXYCHOLESTEROL  
Cholesterol metabolism in the brain is much more complex then described above83, and many 
questions remain unanswered. Similar to the 24S-OH elimination of cholesterol from the brain, 
peripheral cholesterol is additionally reversely transported from the body to the liver in the 
oxidized form, 27-hydroxycholesterol (27-OH)84. 27-OH is produced by the enzyme sterol 27-
hydroxylase (CYP27A1) present in the mitochondria and distributed throughout the body 
though in extremely low levels in the brain92. This oxysterol is the most abundant cholesterol 
metabolite in the plasma of humans and rodents85. 27-OH also possesses the ability to cross 
lipophilic membranes more easily than cholesterol and is therefore able to traverse the BBB86,87. 
Despite substantial uptake of this oxysterol into the brain, its levels in the brain remain low due 
to its efficient metabolism92. This is performed by the action of several enzymes including 
oxysterol 7α hydroxylase (CYP7B1) and 3β-hydroxy-C27-steroid dehydrogenase/isomerase 
(HSD3B7) forming the major 27-OH metabolite, 7α-hydroxy-3-oxo-4-cholestenoic acid (7-
HOCA), which is excreted via the BBB and has a net outflux from the brain into the 
circulation88,89.  
27-OH has also been shown to influence the synthesis of cholesterol in vitro90-92,thus having 
important repercussions on the homeostasis of brain cholesterol in vivo, to which Ali et. al. have 
shown that 27-OH has a slight inhibitory effect on cholesterol synthesis in the brain93. In light of 
the effect of high blood cholesterol on AD, the levels of 27-OH correlates with plasma 
cholesterol levels94, where feeding a high fat diet to rabbits markedly increased the levels of this 
oxysterol in the plasma95. As expected, an accumulation of this oxysterol was present in the 
brains of eoAD and sporadic AD88,96. This increase was also evident in the CSF of AD patients97. 
Additionally, the plasma levels of 27-OH was observed in several neurodegenerative diseases to 
be reduced and its potential as a biomarker was postulated, though more extensive studies need 
to be performed to accurately assess its suitability98. 
In view of its increased presence in the brain of AD, does 27-OH have a role in the disease?  
Treating cells and tissue slices with 27-OH resulted in higher production of amyloid beta and 
phosphorylated tau99-101. Additionally, aged APP mice exhibited higher levels of 27-OH in their 
brains88. 27-OH treatment on neuroblastoma cells also resulted in endoplasmic reticulum stress 
mediating the reduced regulation of leptin, which is associated to AD102. Apart from the 
previously described effects, 27-OH has a potential to affect the BBB by increasing the 
expression of cholesterol transporters ATP Binding Cassette Subfamily A Member 1 (ABCA1) 
and ATP binding cassette transporter G1 (ABCG1) in endothelial cells lining the brain capillaries 
and brain pericytes103-106. Whether or not these transporters are important for the integrity and 
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function of the blood-brain barrier in vivo has not been established. The BBB is also responsible 
for regulating the cerebral pool of amyloid beta by preventing its entry or allowing its 
elimination. In theory, 27-OH may affect this process by increasing the expression of ABCB1 
thereby reducing the entrance of amyloid beta into a brain, though not much is known about 
how it influences the elimination of this peptide from the brain104,105,107.  Interestingly, the 
metabolite of 27-OH processing, 7-HOCA was increased in patients with dysfunctional BBB and 
therefore stipulated to be a marker of the BBB integrity108.  
Despite the lack of in vivo evidence describing the effects of 27-OH on the brain, this oxysterol 
influences several systems peripherally. This cholesterol metabolite has been shown to be a risk 
factor for breast cancer due to its action on the estrogen receptor (ER)109,110. As a selective 
estrogen receptor modulator, 27-OH mediated the growth of ER-positive high-grade tumors. In 
addition, it further acts by influencing liver X receptor (LXR) signaling that may stimulate 
metastasis111. Bone homeostasis is also another system that is affected by this cholesterol 
metabolite, where 27-OH is the linking factor between metabolic diseases and osteoporosis via 
its action on ER, thereby causing higher bone resorption with complementary reduced bone 
formation and ultimately decreased mineral density in bones112. All these data indicate that 27-
OH has a prominent role in disease mechanisms much more then a sheer reverse cholesterol 
transporter.  
A recent publication has highlighted the lack of evidence of the relationship between blood 
cholesterol and cardiovascular mortality. Here they underplayed the effect cholesterol had in 
cardiovascular disease (CVD), however interestingly patients with advanced atherosclerosis often 
had increased levels of 27-OH in their circulation94,113. Furthermore, 27-OH was the most 
prevalent oxidized cholesterol in atherosclerotic plaques, with its accumulation seemingly 
correlated to severity of the lesion and the affluence of macrophages114. This oxysterol may 
mediate an inflammatory cascade via macrophages and endothelial cells with increased release of 
cytokines such as TNF-α, IL-1β mRNA and IL-6115.  These cytokines also contributed to the 
instability of atherosclerotic plaques by causing matrix degradation following the increased 
expression of the matrix metalloproteinases 9, which was also increased with 27-OH 
treatment116. 
The effects of 27-OH on many of these diseases may be specific to their respective affected 
tissue, though the mechanism of how it exerts its action may be somehow similar in the brain. 
Thus more evidence is needed to affirm what this peripheral oxysterol accomplishes in the brain 
and how it does so. With this regard, this thesis expands the current state of knowledge of the 
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influence of 27-OH on the brain, attempting to bridge the many gaps present and illuminating a 
role for this oxysterol beyond a mere cholesterol intermediate. 
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2 AIMS 
The cholesterol metabolite, 27-OH, is known to cross the BBB. While many have correlated its 
presence in the brain with neurological diseases, little is known about its function within this 
cerebral refuge. Thus, this thesis aims to investigate whether 27-OH does have an active role in 
propagating pathological states in the brain.  
Specifically, the aims include:  
§ Examining the level of 27-OH in Alzheimer’s disease and its relationship with other 
pathological markers. 
§ Investigating the role of 27-OH on the brain renin angiotensin system. 
§ Analyzing and scrutinizing the effects of 27-OH on cognitive function and glucose 
metabolism. 
§ Exploring the relationship between inflammation and 27-OH in the brain.  
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3 METHODOLOGY 
This thesis is generated with the use of many methods, spanning both cellular and molecular, in 
probing the brain’s machinery. Here, a brief account of some of the methodologies is discussed. 
However, please refer to the respective papers for a more comprehensive presentation of the 
applied models and methods.   
3.1 EXPERIMENTAL MODELS 
3.1.1 Mice Models 
All the mice models used throughout the thesis are based on the C57BL/6 mice. These mice are 
widely used and are ideal as a general multipurpose model, diet-induced model and for the 
development of transgenic/knockout models. For our purposes we have used only male mice, 
and while eliminating hormonal differences, variations were inevitable. When using genetically 
modified mice, wild-type littermate controls were the control of choice in all experiments. All the 
animals were housed in a Makrolon type II cage with a wire top (Tecniplast, Sweden) and lived 
on a 12-h light-dark cycle with controlled humidity and temperature. The food (normal chow 
feed) and water were provided ad libitum. 
3.1.1.1 High fat induced mice  
Mice were purchased from B&K, Sweden. For nine months, 5-6 week-old mice were separated 
into two groups; one fed a normal diet (ND)(R34) while the other a high fat diet (HFD) 
consisting of 21% fat and 0.15% cholesterol (R638, Lactamine, Sweden). The level of plasma 
lipids was analyzed after 18 weeks to monitor the effects of the diet on the mice. At this time-
point, the cholesterol plasma level was almost double in the HFD-fed mice compared to their 
ND controls (2.78 ± 0.55 vs. 1.51 ± 0.56 mmol/L, P = 0.0011).  
3.1.1.2 CYP27A1-overexpression mice (Cyp27Tg) 
CYP27A1-overexpression mice were bred from our own colony within our animal facilities. 
The colony was initiated with founder mice provided by Eran Leitersdorf, who has developed 
and characterized these transgenics117. This mouse provides a useful model to study the in vivo 
effects of higher levels of 27-OH, mimicking the complexity that cannot be imitated in a petri 
dish. This model is also beneficial as there are no significant differences in total plasma 
cholesterol, triglycerides and phospholipids between these transgenic mice and their 
counterpart littermate controls. Furthermore, these mice exhibited 11-fold higher brain levels 
of 27-OH than controls93. It is important to mention that despite this strikingly higher level of 
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27-OH in the brain, it still constitutes only 10% of the level of 24S-OH, whereas in wild-type 
mice 27-OH is less than 1% of 24S-OH levels. Since 27-OH is predominantly produced 
extracerebrally, its effects in the periphery may influence the brain in a manner that is 
indistinguishable in our paradigm. We therefore have addressed this concern with the addition 
of another mouse model, i.e. 27-OH injected intracerebroventricularly described below. 
Characterizing the behavior of these mice was performed and is described in paper III.  
3.1.1.3 Cyp27a1 Knockout mice (Cyp27-/-)  
Being a valuable model in studying the effects of increased 27-OH; the Cyp27Tg model does 
come with certain biases, allocating any finding to that single variable. Thus the Cyp27a1 
knockout mouse offers another perspective in probing the validity of these findings and their 
association to 27-OH. The generation of the original knockout mouse was previously described 
in detail118. The expansion of these Cyp27-/- mice in our Swedish facilities along with its 
challenges were also detailed earlier119. Noteworthy, these mice surprisingly exhibit normal levels 
of cholesterol despite a significant decrease in the rate of bile acid synthesis, which consequently 
leads to the reduced absorption of intestinal cholesterol118.  In paper III, a subset of the Cyp27-/- 
mice were fed 0.05% cholic acid for 16 weeks. The behavioral characterization of these mice 
revealed no significant changes in spatial memory compared to controls and feeding these 
knockout mice a high fat diet, while detrimental to the wild-type, did not modify their behavior 
either120. 
3.1.1.4 Intracerebroventricular 27-OH injected mice (ICV27-OH)  
As previously explained, this mouse model provides the added benefit of ensuring that the 27-
OH-mediated responses are purely due to its central actions within the brain, thus eliminating 
offshoot peripheral effects.  Seven-eight week-old C57BL/6 mice were fixed on a stereotaxic 
frame (David Kopf Instruments) with a heated pad (37°C) to maintain normal body temperature. 
Anesthesia was administered by inhalation of isoflurane/oxygen mixture at 4-5% and maintained 
throughout the duration of the surgery at 1.5-2%. The injections were performed bilaterally into 
the lateral ventricle using the following coordinates: -0.9 mm anteroposterior, ± 1.4 mm laterally 
from the bregma and 2.0 mm from the skull surface, in accordance to the Paxinos mouse brain 
atlas121. The injected 27-OH, was bound to the high-density lipoprotein (HDL) protein at a 
concentration ratio of 1:3 and incubated for 1 h at 37°C. This bound 27-OH was then diluted in 
artificial CSF (aCSF) to a concentration of 5 and 10 µM. The control group was injected under 
similar conditions with HDL diluted in aCSF. A 10 µl gauge Hamilton syringe was used to 
deliver 1 µl of the solution into each hemisphere. 
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3.1.2 Human Subjects 
The use of animal models allows manipulation in elucidating mechanisms important in disease 
pathogenesis/progression. Findings from animals however are limited in its translation or even 
mirroring of disease states in humans. It is thus imperative to be cautious when extrapolating 
results from animals, especially when trying to implement or even correlate these to humans. To 
this aim, we have tried to bridge this gap by utilizing human subjects to implement a more 
translational approach. The patient cohorts used in this thesis were specifically sampled based on 
the proposed scientific questions and are therefore grouped based on the individual respective 
papers.   
3.1.2.1 Paper I  
CSF samples were collected from patients recruited at the Karolinska University Hospital 
memory clinic. A cross-sectional cohort consisting of 25-28 Controls, 8-10 MCI and 20-21 AD 
patients were enrolled. The control group consisted of subjective cognitively impaired 
individuals. These individuals are generally considered old and have non-specific memory 
complaints, revealing no memory-related deficits upon objective testing.  
Mild cognitive impairment (MCI) was described by Winblad et al. and is defined upon these three 
criteria122:  
i. Not demented, however are not considered normal either. These patients do not fulfill 
the criteria for a demented diagnosis according to either the Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition (DSM-IV) or the International Classification 
of Mental and Behavioural Disorders (ICD-10).  
ii. Experience cognitive decline assessed either subjectively by the patient and/or an 
informant and additionally exhibiting impairment on objective cognitive tasks or the 
declined performance over time in objective cognitive tasks. 
iii. The patient has minimal impairment in complex instrumental functions alongside intact 
basic daily living activities.  
While the term generally refers to a transitional stage before the onset of clinical AD, it 
encompasses far more than just a prodromal AD zone122. This heterogeneous group includes 
different classifications where some revert to normal cognitive capabilities and others progress to 
AD. It is important to note that all the patients described as MCI in our study developed AD 
during the following 3 years. Finally, the DSM-IV was used in the diagnosis of the included AD 
patients in the study. They were further assessed based on a comprehensive clinical protocol 
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including clinical examination, detailed psychological assessment, magnetic resonance imaging 
(MRI), single-photon emission computed tomography brain imaging, electroencephalography 
and the analysis of CSF and blood (total-tau, phospho-tau and Aβ1-42), all detailed in Table 1 in 
paper I.  
With regards to the brain samples used in the study, the postmortem material was acquired from 
the brain bank at the Karolinska Institutet. The patients included 4 AD and 3 age-matched 
controls. The AD samples consisted of two males, 79 and 89 years-old and two females, 76 and 
80 years-old whereas the controls were two males, 66 and 83 years-old and one 83 years-old 
female. As for the AD patients, they exhibited a Mini-Mental State Examination (MMSE) score 
between 2 and 15 and were clinically diagnosed as probable AD (DSM-IV) in addition to the 
CERAD neuropathological criteria.  The postmortem delay was between 24-48 h and the 
temporal cortex was used.   
3.1.2.2 Paper II 
A human model, depicting the Cyp27Tg mouse model, in having excessive levels of 27-OH in 
the blood was used here. These patients suffer from hereditary spastic paraplegia 5 (SPG5), 
having an autosomal recessive mutation in the Cyp7b1 gene123. This encodes for the oxysterol 7α-
hydroxylase, which facilitates an important step in the synthesis of bile acids from cholesterol by 
acting on 27-OH. A consequence of this mutation is the accumulation of 27-OH in the blood, 
hence the levels of this oxysterol is 6-9 fold higher compared to controls124.  The CSF of these 
patients have extremely high levels of 27-OH ranging a 30-50 fold increase. While 25-OH, 
another form of oxysterol was also increased in serum, this was not mirrored in the CSF of these 
patients. It is also worthy to note that the total cholesterol levels in the plasma are unchanged, a 
finding also present in the Cyp27Tg mouse model. These patients are clinically characterized by a 
progressive type of spastic paraplegia of a variable onset, while pure in most cases, it can 
however express mild cerebellar ataxia and optic atrophy. Even though these patients have 
normal MRI scans, this subset of hereditary spastic paraplegics is distinguished by the primary 
demyelination of the pyramidal tracts in the absence of peripheral neuropathy123. Despite the 
myriad degenerative signs present in these patients no changes were seen in the CSF tau and 
phospho tau protein levels124.   
3.1.2.3 Paper III 
This study tests the hypothesis that higher CSF levels of 27-OH are associated with reduced 
glucose uptake in humans. To this aim, we recruited 75 individuals who have undergone 18F-
FDG PET imaging at the Radiology department at the Karolinska University Hospital. No 
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criteria were employed when selecting these individuals other than having underwent PET 
scanning. From these subjects only 34 had CSF samples collected which is needed to determine 
the levels of 27-OH. The randomness of the selection process enabled the assembly of a 
heterogeneous group of neurological diseases adding to the strength of our cohort despite the 
small number. These patients all underwent a comprehensive cognitive evaluation by a 
neuropsychologist according to the procedures of the memory clinic at the Karolinska University 
Hospital. The diagnoses were set according to the ICD-10 and are displayed in supplemental 
Table 2 in paper III. The clinical setting of these PET scans, forced the implementation of 
tighter research criteria to eliminate inaccurate observations. Thus the time between injection of 
the radioligand and scanning should not be less than 30 and over 45 minutes, thereby excluding 
11 patients from our cohort. The levels of 27-OH may be slightly modulated by cholesterol 
modifying drugs125 therefore two further patients were excluded from the study. This led to the 
remainder of the sample having normal cholesterol levels despite the large variation in the levels 
of 27-OH in the CSF. Highlighting this hidden population and the importance of monitoring the 
levels of 27-OH, which need not mirror that of cholesterol. 
3.1.3 Cell cultures 
The simplicity of cell cultures being their advantage over in vivo models is ironically also its 
limitation.  Their flexibility in applications and ease of use allows their continual survival as an 
experimental model. Throughout this thesis when probing cellular mechanisms we used to a 
large extent rat primary cultures in addition to neuroblastoma (SH-SY5Y). Rat primary neurons 
and astrocytes were prepared from unborn embryos. These cells enable the mirroring of brain 
processes in a more convenient and easy to handle method. Being either predominantly neuronal 
or astrocytic cultures, the communication between the different cell types is a major obstacle in 
these cultures. They do however readily allow genetic manipulation in a reproducible fashion, 
which we have employed here with the use of siRNAs. Primary neuronal cultures are post-
mitotic whereas neuroblastomal neurons are not. Neuroblastomas are derived from a neuronal 
tumor and therefore may differ from healthy neurons. They however need no ethical permit to 
use and therefore have the added benefit of accessibility over primary cultures. 
3.2 ETHICAL CONSIDERATIONS 
Research is governed by morals that form the code of conduct. These codes which researchers 
must adhere to, allow scientific advancement not only through collaboration but enabling the 
reproducibility of data to name a few. Accordingly, any research being conducted must be 
examined and approved by an ethical review board. These boards comply with the much-
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recognized Helsinki Declaration. In this thesis, the use of humans and animals were approved by 
the appropriate regional ethical committee for Stockholm and are detailed below: 
Human CSF: DNR: 2007/697-31/1 
Human Brain: DNR: 024-01; DNR: 2011/692-31/1 
Rat primary cultures: DNR: S16-09; DNR: S194-11; DNR: S45-15 
Mice: DNR: S139-10; DNR: N578-11; DNR: S51-13; DNR: S141-12; DNR: S57-15   
With regards to the use of rat primary cultures, when possible was substituted with 
neuroblastoma cells in compliance with the replacement aspect of the 3R principles of animal 
research. Furthermore, all the patients involved in this thesis granted their consent. 
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4 RESULTS AND DISCUSSION 
4.1 ALZHEIMER’S DISEASE AND ITS PATHOLOGIES 
Alzheimer’s disease although being considered a multifactorial disease is restricted to two 
characteristic pathologies, amyloid plaques and tau tangles. The changes of these proteins 
reflected in bodily fluids such as the blood and CSF are considered biomarkers for the disease. 
Within our cohort, the CSF levels of total and phosphorylated tau were increased and Aβ1-42 
decreased in the AD patients compared to controls (Paper I). Cholesterol levels surprisingly did 
not exhibit any changes in either plasma or CSF, however its metabolites 27-OH and 24S-OH 
were modified. The plasma levels of both these oxysterols were significantly reduced, with this 
decrease being observed even earlier within the MCI group. The CSF 27-OH levels were 
elevated while the 24S-OH levels revealed an increased trend in the AD patients. These findings 
have been previously described and the potential use of oxysterols as biomarkers for 
neurodegeneration, although proposed, has not gained momentum98,126.  
In concurrence with prior findings, ACE levels in the CSF were not only increased in the AD 
patients but also in the MCI sample127. Our study also highlighted the previously unknown 
increase of the precursor angiotensinogen (AGT) in both MCI and AD patients. ACE and AGT 
constitute an important rate-limiting enzyme and the main precursor of the renin angiotensin 
system respectively. This system, completely independent from its renal counterpart, is known to 
regulate cerebral blood flow, influence the autonomic system and processing of memory28. 
Furthermore, the involvement of this system is not only being recognized in AD but also in 
other neurological disease such as stroke and depression29.  
In AD the levels of the cholesterol metabolites in addition to members of the brain RAS are 
modified, and whether these are unrelated coincidences or have some sort of connection was 
formerly unexplored. To further examine this relationship, we compared the levels of 27-OH 
and 24S-OH with the CSF levels of ACE. A positive correlation in both plasma and CSF levels 
of 27-OH existed with ACE in the MCI-AD group even after correcting for age and gender, 
though this relationship was not seen in the control group. Moreover, no correlation between 
plasma or CSF levels of 24S-OH and ACE was observed. This relationship forged a new path of 
research that we set out to investigate featured in the subsequent chapter. 
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4.2 BRAIN RAS IS MODULATED BY 27-HYDROXYCHOLESTEROL  
It is important to state that the correlation study only indicates a relationship where having 
higher levels of 27-OH shows a tendency of exhibiting higher CSF ACE levels in AD patients. 
Thus to address the issue of whether 27-OH alters ACE levels causatively, we treated primary 
neurons with 27-OH.  This resulted in the increased expression of ACE in addition to the 
precursor AGT and the downstream angiotensin II type 1 receptor (AT1R) (Paper I and II). At 
the protein level, the secreted AGT was higher in both neurons and astrocytes, while higher 
cellular amounts were only observed in neurons. To probe whether this increase led to a 
functional outcome with regards to cellular signaling of the RAS cascade, the downstream 
AT1R-mediated JAK/STAT activation was assessed128. The phosphorylated STAT3 (Tyr-705), 
indicating an active STAT3, was elevated in neurons treated with 27-OH. This heightened 
phosphorylation was however inhibited when losartan, a specific AT1R antagonist, was used.  
The effects of 27-OH observed thus far are within the in vitro paradigm and may not translate to 
the complex situation within the human body. Therefore, in Paper II we employed the Cyp27-/-
mouse, incapable of synthesizing 27-OH, these mice showed no significant increase in ACE 
expression. Additionally, lower levels of AGT and phosphorylated STAT3 were seen in the 
cortices and hippocampi of these mice. Forming a larger translational picture the SPG5 patients, 
having a 30-50 fold increase in 27-OH CSF levels, expectedly had contrary findings to the  
Cyp27-/- mouse. These patients revealed higher levels of both the precursor AGT and the 
AngI/II in their CSF.  
In view of the current data, we speculated that 27-OH leads to the observed increase in ACE 
and AGT. Levels of CSF 27-OH are seen to be higher in AD patients while plasma levels show a 
reduction, which is evident even earlier within the prodromal AD stage. We have also observed 
that these patients have elevated levels of both ACE and AGT. The obvious question of whether 
27-OH initiates this elevation in patients is crucial to answer and our investigation in both in vitro 
and in vivo models points towards an influential role as displayed in Fig. 3. In fact, the use of 
statins, although controversial in improving cognition, showed some reduction in the incidence 
of dementia129, while the use of ACE inhibitors enhanced cognitive performance in addition to 
improving learning and retaining memory in animal studies130,131. Within CVD, reaching the 
cholesterol-lowering goal with statins alone still had some residual risk for CVD, a risk that was 
decreased with the combined use of ACE and AT1R antagonists132. This is an important finding 
that may have some resounding implication for the brain.   
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Fig. 3. A Schematic overview of the mechanism by which 27-OH influences the Brain RAS. 
4.3 THE ROLE 27-HYDROXYCHOLESTEROL PLAYS IN COGNITION AND 
GLUCOSE UPTAKE 
The upregulation of brain RAS due to 27-OH was observed on ACE, AGT and AT1R, which 
are the rate-limiting enzyme, the precursor substrate and the receptor respectively. These are 
important players within the brain RAS, however, the memory related action of RAS was found 
to revolve around the AT4R and its ligand AngIV. AngIV affects learning and memory through 
its inhibitory control of AT4R, also known as the insulin-regulated aminopeptidase (IRAP)133,134. 
This increase in cognition is believed to be associated to either heightened neuronal glucose 
uptake135 or the reduction of the receptors-cleaving action on memory-associated neuropeptides, 
among other hypotheses136,137.  
In our paradigm, 27-OH increased both the expression of IRAP and its activity (Paper III). This 
was not only seen in vitro the Cyp27Tg mouse in addition to ICV27-OH also exhibited this 
increase. The effect of 27-OH extended to the enzymes converting AngII to AngIII and the 
degradation of AngIV, i.e. increasing aminopeptidase (AP) A and AP-N respectively. To further 
clarify the roles these enzymes play in maintaining the levels of AngIII and AngIV and 
consequently their effects on both IRAP and glucose uptake, we knocked down their 
expressions. Treating neurons with AngIII alone led to similar effects as 27-OH i.e. increased 
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IRAP activity and reduced glucose uptake. Thus siRNA against AP-A caused less production of 
AngIII, which led to the negation of the 27-OH-mediated effects. On the contrary, AngIV 
treatments maintained the catalytic activity of IRAP at control levels, although elevating its 
expression and surprisingly increased glucose uptake even more than insulin. Knocking down 
AP-N led to the accumulation of AngIV, which reduced the effects of 27-OH on IRAP and 
glucose uptake. Furthermore, the use of Bestatin, an inhibitor of a range of metallo-
aminopeptidase leading to the accumulation of AngIII while reducing AngIV production, 
resulted in comparable effects on glucose uptake and IRAP activity as 27-OH.  
These series of experiments consolidate a new function for AngIII on both glucose uptake and 
IRAP activity along with mediating the action of 27-OH within the brain. They also emphasize 
the modulation by 27-OH of the levels of AngIII and AngIV by altering the expression of the 
enzymes important in maintaining a balance between the function of both these RAS mediators 
(Fig. 3). Although insightful these experiments do not elucidate the in vivo consequence of the 
previously discussed alterations. Thus scanning the Cyp27Tg mouse using 18F-FDG PET 
revealed the reduced uptake of glucose generally across the entire brain of these animals (Paper 
III). This was associated with lower levels of GLUT4, while the levels of GLUT3 and GLUT1 
remained unchanged. The testing of spatial memory of these mice revealed longer escape 
latencies and less time in the correct quadrant than their counterpart WT-littermates. A marker 
for long-term memory consolidation, activity-regulated cytoskeleton-associated protein (Arc) was 
also decreased. While it is difficult to assess causation of 27-OH in reducing glucose uptake in 
humans, we have showed a negative relationship between both with findings in a random sample 
of patients (Paper III). These patients had various diseases and thus not limited to a certain 
disease scope, and more importantly all had normal levels of cholesterols. They also displayed 
varied cognitive ability as disclosed by the MMSE scores and the memory-related diagnoses. This 
cohort emphasizes that measuring 27-OH may be more relevant than cholesterol within 
neurodegenerative diseases, especially since cholesterol during later stages of life has a 
controversial relationship with dementia risk138. Additionally, cholesterol does not traverse the 
BBB and that cholesterol produced in the brain is formed within this refuge86. 
4.4 27-HYDROXYCHOLESTEROL MEDIATES BRAIN INFLAMMATION VIA 
S100A8 
The role of inflammation within neurodegenerative disease has gained wide support in the past 
several years. Reviewed here, there are many mechanisms for the induction and persistence of 
inflammation within these diseases139. Even though 27-OH has not been described to have a role 
in inflammation within the brain, it propagates inflammatory processes seen in other diseases 
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such as atherosclerosis and chronic obstructive pulmonary disease115,140. Previously, we have 
shown that a HFD leads to the upregulation of the genetic expression of S100A8 in the brains of 
mice141. Thus in Paper IV, we investigated the effects of 27-OH, which revealed an increase in 
the expression of S100A8 in astrocytes. S100A8 is a member of the S100 calcium-binding 
proteins, which are involved in inflammatory response in addition to other cellular processes and 
seen to be elevated in AD142. We have established previously that S100A8 is increased and 
aggregated in the brains of several mouse models overexpressing APP143. This accumulation 
occurs earlier than the development of Aβ plaques. Furthermore, S100A8 binds to, RAGE, 
which is also elevated in the presence of 27-OH. The activation of this receptor leads to the 
downstream induction of the expression of BACE1, an enzyme that takes part in producing 
Aβ144. Therefore, increased levels of BACE1 by 27-OH indicated that RAGE is activated. This 
activation is also elucidated by the nuclear translocation of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB) by 27-OH. RAGE is known to activate NF-kB, promoting 
the induction of both itself and BACE1145. Moreover, the use of a NF-kB inhibitor prevented the 
increase of RAGE initiated by 27-OH.  Both our in vivo mouse models, with increased levels of 
27-OH, had elevated levels of S100A8, its receptor RAGE and the downstream BACE1 (Paper 
IV).  These findings illuminated in Fig. 4 implicate 27-OH in mediating inflammation within the 
brain and suggests a role in the accumulation of Aβ plaques in AD. 
 
Fig. 4. A Schematic overview of the mechanism by which 27-OH induces inflammation in the brain. 27-OH via 
RXRγ (explained in more detail in section 4.6) increases the expression and aggregation of S100A8 in astrocytes. 
Through RXRγ 27-OH also increases the levels of RAGE in both astrocytes and neurons respectively. RAGE 
signaling mediated via NF-kB is increased which in turn raises the levels of both RAGE and BACE1. 
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4.5 DOES 27-HYDROXYCHOLESTEROL MEDIATE THE NEGATIVE 
CHOLESTEROL EFFECTS ON THE BRAIN? 
The risk of dementia due to increased cholesterol and dysregulated cholesterol metabolism has 
been studied tremendously and while still some controversy exists as to how, there is no doubt 
that it does contribute to neurodegenerative diseases86. Even though cholesterol does not cross 
the BBB, it is implicated in different pathways leading to AD146. However, the levels of the BBB-
traversing 27-OH correlate with the circulatory cholesterol levels94. Furthermore, production of 
27-OH seems to be an alternative method for the reverse transport of peripheral cellular 
cholesterol, having a large influx to the liver84. This led to the concept that 27-OH may mediate 
negative effects on the brain, a hypothesis given by others and us86,95,147.  
Indeed, an enriched cholesterol diet and 27-OH has led to the increase in Aβ production in the 
brain of rabbits148. In our studies, HFD mice showed an increase in several RAS components, 
mainly ACE and AGT. Additionally, the downstream signaling of the AT1R leading to the 
phosphorylation of STAT3 was also increased in these mice (Paper II). These changes were 
apparent in the in vitro treatment with 27-OH, but were reversed in the Cyp27-/- mice. The 
behavioral changes that we have witnessed with the Cyp27Tg mice were also present in HFD-fed 
mice. Reported in Heverin et. al., the deficits seen in spatial learning were propagated by the 
enriched cholesterol diet and consequently were absent in Cyp27-/- mice fed with the same diet120. 
This was also confirmed with the reduced levels of Arc in the WT mice fed with a HFD, similar 
to the Cyp27Tg mice. On the contrary, normal levels were observed in the Cyp27-/- mice, 
whether fed a normal or HFD diet.  
The effects of 27-OH on IRAP catalytic activity were also mimicked in the brains of mice on an 
enriched cholesterol diet, indicating higher activity (Paper III). While we did not show how this 
diet affected glucose uptake, it led to a reduction albeit for a short period due to the rebound of 
GLUT1149. The brain immune system does not seem to be spared either as a HFD also led to the 
increase in S100A8, an inflammatory mediator, a phenomenon also seen in 27-OH treated cells 
or upon overexpressing the 27-OH-producing enzyme in mice (Paper IV). Activated microglia 
and the release of pro-inflammatory cytokines were also among the other features a HFD mice 
elicited150. Taken together these evidences emphasize that 27-OH may indeed arbitrate the 
negative effects of high cholesterol. 
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4.6 THE ROLE OF NUCLEAR RECEPTORS IN PROPAGATING THE 
ACTIONS OF 27-HYDROXYCHOLESTEROL 
It is well known that 27-OH is a ligand for LXR, and that the nuclear receptor plays an 
important role in mediating cellular functions. LXR regulates cholesterol metabolism and here 
we show that its ligand 27-OH functions beyond the known control of cholesterol metabolism, it 
also upregulates several components of the brain RAS. Therefore it seemed appropriate to 
investigate if these effects are also propagated via this receptor, which we did using both a 
pharmacological and siRNA approach.  
TO-901317, a potent synthetic LXR agonist with no selectivity for either LXR isoform151, caused 
a significant increase in the expression of ACE, AT1R and secreted AGT (Paper II). 
Surprisingly, it also led to a decrease in the intracellular expression of AGT, unlike both 
oxysterols. Blocking LXR with 22(S)-OH, an inactive isomer of 22(R)-OH152, eliminated the 
effects of 27-OH on the expression of ACE and AGT in addition to its secreted levels. Although 
22(S)-OH did not completely abolish the increased expression of AT1R by 27-OH, knocking-
down the expression of LXRβ did. Furthermore, siRNA of LXRβ eliminated the action of 27-
OH on the expression of ACE, renin and AGT. We chose to knockdown LXRβ as it is more 
widespread within the brain than the LXRα isoform153. The effect mediated by 27-OH via LXR 
on RAS extended further downstream to include AT4R/IRAP, a receptor important in cognition 
in addition to AP-A and AP-N, disrupting the balance between AngIII and AngIV (Paper III).  
However, LXR did not seem to propagate the proinflammatory action of 27-OH. 22(S)-OH did 
not block the action of 27-OH on the expression of both S100A8 and RAGE (Paper IV). Since 
LXR forms heterodimers with the retinoid X receptor (RXR) we hypothesized that 27-OH may 
also bind to RXR154. By using siRNA to reduce the expression of RXRγ, the 27-OH-mediated 
increase of both S100A8 and RAGE were ameliorated. 27-OH also mediates the release of 
inflammatory cytokines in atherosclerosis via ER, we have not tested this alternative hypothesis 
within our paradigm however 27-OH being a SERM may exert a different action in the brain via 
ER. Within our experiments we have seen that indeed RXRγ and not LXR mediated the 
proinflammatory effects of 27-OH. 
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5 CONCLUSIONS AND FUTURE CONSIDERATIONS 
Here in this thesis, we propose that 27-OH is a common thread connecting many of the 
mechanisms identified through the GWAS implicated genes10 highlighted in Fig. 5. Alzheimer’s 
disease and other dementias are multifactorial in etiology. Many factors such as oxidative stress, 
inflammation, protein aggregation, insulin/glucose metabolic dysfunction, hypertension and 
indeed cholesterol metabolic deficits may play a role in either initiating or propagating these 
crippling diseases.  
We show that CSF and plasma 27-OH is pathologically altered not only in AD, but also earlier 
within the prodromal phase MCI. This increase in CSF 27-OH is not limited to AD as it was 
seen in patients diagnosed with other diseases with various forms of cognitive impairment. 
Although all of these individuals are normocholesterolemic, some observed higher levels of CSF 
27-OH, highlighting a subgroup exhibiting higher production or reduced metabolism of 27-OH. 
The number of patients included, though validating a proof of concept, restricts this study. Thus 
it must be further investigated on a larger cohort to consolidate whether the levels of 27-OH can 
mirror a decreased brain glucose metabolism/cognitive state or hint at a diseased state that must 
be interjected. While the use of 27-OH as a diagnostic marker is still debatable, a meta-analysis 
by Wang et. al. regarding CSF levels of this oxysterol shows its additive benefit126.  
Our studies also add to the evidence regarding the use of statins. Statin use within dementia is 
extremely controversial with many doubting their benefits155. In addition, high blood cholesterol 
levels itself, though correlating with the above diseases, have not revealed any links to causation 
or mechanism156. Thus it does not make sense for statins, which are capable of crossing the BBB, 
to be used in reducing the production of brain cholesterol, an important player in the plasticity 
and synaptic ability of the brain. Furthermore, plasma cholesterol does not cross the BBB and is 
unable to cause any harm to the brain while 27-OH does and its levels correlates with cholesterol 
in the blood94. Thus statins peripherally may have a role in reducing 27-OH levels, as most of this 
oxysterol emanates from the circulation. Some statins have shown beneficial effects in reducing 
the incidence of dementia129, which may be explained by the reduction of 27-OH levels which 
closely accompanies decreases in cholesterol levels. Statins such as simvastatin can cross the BBB 
and cause negative memory complaints as seen in patients on high doses, these side-effects 
would be less expected with the use of polar statins such as fluvastatin. Moreover, cholesterol 
heavily linked to CVDs is now also under scrutiny, recent research has weakened the link 
between the two in elderly people157. Importantly, the most abundant form of cholesterol present 
in atherosclerotic plaques is 27-OH, which was also greatly implicated in the atherosclerotic 
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processes158,159. Therefore it maybe more pertinent to monitor this oxysterol and attempt to 
reduce its levels rather than control the levels of cholesterol in the blood. The choice of Cyp27a1 
as a drug target to reduce the levels of 27-OH has only been featured in one paper, revealing that 
27-OH can be decreased without altering cholesterol metabolism160, which has an important 
practical significance in the development of a more potent and selective inhibitor.  The use of 
Cyp27a1 inhibitors against breast cancer has been patented, in anticipation of the publication 
elucidating the deleterious effects of 27-OH110,161. 
The function of the brain RAS goes beyond the control of cerebral blood flow and hypertension 
as it is also involved in mediating memory by the action of AngIV28. This thesis emphasizes the 
role 27-OH plays in upregulating the entire system, affecting AngIV levels and altering both 
cognition and glucose uptake in mice. It mechanistically does this by increasing AP-A, AP-N and 
IRAP expression thus increasing the catalytic power of the latter. This leads to the reduction in 
the levels of AngIV and higher amounts of AngIII, accentuating the previously unknown action 
of AngIII in inhibiting glucose uptake and increasing IRAP activity. The interplay between IRAP 
and GLUT4 is important, within our paradigm they seem to have an opposite effect i.e. IRAP 
activation occurs simultaneously with GLUT4 inhibition and vice versa. GLUT4 is described to 
contribute largely to the memory-involved cognitive function by taking up the much-required 
glucose162,163. Therefore both these molecules contribute in some form to memory-related tasks.  
 
Fig. 5. The effects of 27-OH on features driving the pathology of AD. 27-OH upregulates the Renin-Angiotensin 
system (RAS) and decreases glucose metabolism thereby influencing memory. This oxysterol also mediates 
inflammation by increasing S100A8 and RAGE. Together these actions propagate neuronal dysfunction an 
important part of AD.  
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Fig. 6. The proposed goals in limiting the negative effects of 27-hydroxycholesterol. 
 
In fact, the translocation of both of them is initiated by certain stimuli including insulin135. 
Previous studies have observed that intranasal insulin exerts beneficial effects on memory164. 
Currently large multicenter phase II and III clinical trials are underway to determine the 
effectiveness of the therapeutic application of intranasal insulin in modifying memory 
(ClinicalTrials.gov Identifier: NCT01767909). Although some mechanisms of how insulin 
improves memory are described, no conclusive evidence is reached164. Here, our results provide 
some mechanistic insight on how insulin may mediate its action centrally, and we show that 
AngIV has an even larger effect in mediating glucose uptake than insulin. Therefore strategies 
modulating this system to allow for the actions of AngIV to linger longer may be advantageous 
for memory, and thus cognition. Several animal studies have shown that intracerebroventricular 
injections of AngIV improved learning and memory165,166, though to date or unbeknown to us, 
no study has ever intranasally introduced AngIV into the human brain.  
While exogenous delivery of AngIV may be one route in achieving better cognition, our data also 
supports the use of IRAP or AP-N inhibitors. IRAP inhibitors mimicking the effects of AngIV 
are currently being developed, with a few non-peptide based inhibitors being identified167. The 
same group previously clarified that IRAP inhibitors improve cognition by increasing dendritic 
spines168. Furthermore, targeting the AngIV-degrading enzyme AP-N is widely used in the 
treatment of cancers. AP-N is a zinc-dependent metalloproteinase that plays an important role in 
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tumor invasion and angiogenesis by cleaving extracellular matrix proteins. A naturally occurring 
AP-N inhibitor is curcumin, which has been shown to inhibit tumor invasion and 
angiogenesis169. Remarkably, curcumin is also featured as beneficial against AD due to its anti-
inflammatory and antioxidant effects170. Further investigations would be required to determine if 
curcumin or other AP-N inhibitors have an effect on memory, however our study illuminates a 
possible new therapeutic pathway in the fight against AD. 
Astrocytes play an important role in AD, from the consequences of astrocytic atrophy due to the 
lack of clearing of Aβ171. Here we show another method by which astrocytes orchestrate its 
action in AD via the secretion of S100A8 triggered by 27-OH. This increased S100A8 expression 
was absent in neurons, thus cementing astrocytic role in propagating inflammation in the brain. 
27-OH also increased the receptor of this inflammatory mediator in both astrocytes and neurons, 
suggesting that there may be communication between both cell types in mediating inflammation 
in the brain. Though not covered in this thesis, this relationship should be investigated to 
elucidate the role each of these cells play within the current mechanism described.  
The binding of 27-OH to RXRγ thereby mediating the S100A8 and RAGE increase was another 
finding that we have elucidated in this thesis. This was surprising as beneficial effects leading to 
decreased amyloid plaques and enhanced soluble Aβ clearance were found with the RXR agonist 
bexarotene172. Strikingly these results were not completely reproducible173,174. This may be due to 
the fact that bexarotene is not isoform selective and also targets RXRγ, which we indicate 
mediates inflammation and possibly amyloid deposition. Previously, we have observed that 
S100A8 aggregation occurs in AD mice models before amyloid plaques. This strengthens the 
conception that mid-life hypercholesterolemia is considered a risk factor for AD62, as we have 
shown that a HFD also led to S100A8 aggregation. In addition, inflammation is now being 
considered an event that precedes amyloid deposition175. Thus the suggestion that 27-OH may be 
a driving force in neuroinflammation leading to the development of AD may not be far fetched, 
though much work is further needed to investigate this. 
The cost of dementia must not be measured by the amount of money spent on the care and 
treatment for patients (which has reached 487 billion USD in 2015)5, but the real cost is the life 
of the single individual, whose own existence has forever changed, affecting the many people 
surrounding them. While it is estimated that this devastating disease afflicts 47 million people, the 
number that this disease truly affects might be tripled or even quadrupled. So far no 
pharmacological intervention targeting amyloid beta has been very promising and the need to 
have a multi-target treatment is currently imperative5. The expansion of our current working 
hypothesis to include pathophysiologies that might indeed have a causative role in the disease 
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mechanism could prove to be of great importance in the fight against dementia. This thesis is 
part of that initiative; an impetus to search beyond the restrictive boundaries of the current AD 
hypotheses held steadfast, and to dare to wander into the unknown emptiness, currently taking 
hold of the minds of our nearest and dearest. 
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6 WHAT DOES ALL THIS MEAN AND WHY YOU 
SHOULD CARE 
For all you non-scientist people, here is a summary of the important points discussed in the 
thesis.  
Cholesterol as many of you know has been and still is considered by many as the “bad guy”. 
Being depicted throughout the past several decades as the cause of cardiovascular diseases, 
stroke, diabetes and even Alzheimer’s disease. The reality of this relationship, as all relationships, 
is much more complicated then it seems to be. The brain, which is the focus of this thesis, 
fortifies itself from the cholesterol in the blood with the help of a very tight barrier. Thereby 
preventing any cholesterol from entering this refuge. Ironically, the brain contains the most 
cholesterol in the body, so where does this cholesterol come from and how does the blocked 
cholesterol in the blood affect the brain?  
The brain has very efficient machinery that manufactures cholesterol from small building blocks 
called Acetyl-CoA, which are able to cross this barrier. All the cholesterol in the brain comes 
from these factories, allowing it to be completely independent from the cholesterol in the blood. 
The brain uses this cholesterol in many things such as creating the outer walls of brain cells and 
coating nerve cells to allow the proper conduction of nerve signals. It is cholesterol that enables 
the brain its flexibility allowing us to be resilient in learning new things. It is therefore imperative 
for the brain to maintain a constant amount of cholesterol. This is achieved by balancing the 
production, usage and the removal of excess cholesterol. 
The elimination of cholesterol from the brain is accomplished by converting the excess into 
another form of cholesterol known as 24S-Hydroxycholesterol (24S-OH), which is then 
discarded outside the barrier into the blood. The foreign counterpart of 24S-OH that is also able 
to pass over this barrier is 27-Hydroxycholesterol (27-OH). I use the adjective “foreign” because 
this oxysterol (oxidized cholesterol; i.e. when oxygen combines with cholesterol) originates 
predominantly from the rest of the body and enters the brain’s sanctuary. The levels of 27-OH 
corresponds to that of cholesterol in the blood, meaning that higher amounts of cholesterol will 
lead to more 27-OH that is able to traverse the barrier into the brain. Hence, we hypothesized 
that 27-OH maybe how cholesterol is able to get around the barrier and enter the brain. Not 
much is known about what 27-OH does in the brain therefore we took it upon ourselves to 
embark on a journey to discover if 27-OH is truly more than just excess cholesterol waste. This 
thesis is a recollection of this journey.  
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Blood pressure is controlled by a system called the renin-angiotensin system (RAS) that is 
generally found in the kidney. However the brain has a similar system that is separate from that 
of the kidneys. The brain RAS also has a say in tuning the blood pressure but is more involved in 
processes that adjusts memory and the function of nerve cells. What we have found is that 27-
OH modifies this system by increasing the levels of many of its key players. These key players 
include Angiotensinogen (AGT)(which is the raw material), Angiotensin-Converting enzyme 
(ACE)(the factory worker) and Angiotensin II (AngII)(the product). We found that the levels of 
these players are elevated in Alzheimer’s disease and they correspond to the amount of 27-OH 
present in the fluid surrounding the brain known as cerebrospinal fluid (CSF). The product, 
Angiotensin II is further modified giving rise to two other forms, Angiotensin III (AngIII) and 
IV (AngIV). This modification process is heightened by 27-OH. In fact what 27-OH specifically 
does is create an imbalance between AngIII and Ang IV. This unevenness prevents the beneficial 
effects of AngIV, which is more glucose entering your brain cells and better memory. In mice 
that we genetically engineered to produce more amounts of 27-OH, we observed worse memory 
and less glucose in the brain. Furthermore, we put individuals into a scanner to measure the 
amount of glucose in their brains and determined how much 27-OH each individual had in their 
CSF. We discovered that the higher the amount of 27-OH an individual has, the less glucose that 
person has in their brains. Trying to understand why this is the case, we realized that 27-OH 
reduces the quantity of a glucose transporter (GLUT4) and consequently uncovered how it does 
this.  
Another feature of Alzheimer’s disease is inflammation. It is now considered to be an early event 
in the development of the disease. Though 27-OH is not known to cause inflammation in the 
brain it does propagate it in atherosclerosis. 27-OH is the most abundant form of oxidized 
cholesterol in the plaques that block arteries. It also aids in the release of molecules that 
promotes the dislodgement of those clogs. Within the brain we have seen that 27-OH also leads 
to the accumulation of a promoter of inflammation, S100A8. This promoter ultimately leads to 
the increase in β-secretase 1 (BACE1), the factory worker who produces amyloid beta, which is 
one of the characteristics of Alzheimer’s disease.  
All the evidences we unveiled point to that 27-OH is much more than a random form of 
cholesterol. It bypasses the barrier that the brain upholds and executes the negative effects that 
cholesterol is thought to cause. Thus reducing cholesterol with medications such as statins that 
are widespread may have some impact in reducing the harmful effects of 27-OH. Though statins 
have not yielded consistent results and have many adverse effects. Some statins even cross the 
brain barrier affecting cholesterol production in the brain and leading to memory disturbances. 
We believe that statins that do not cross may therefore be more beneficial due to their fewer side 
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effects in the brain. However, it is much more worthwhile to target 27-OH directly through 
curbing its production. We have also illuminated several points that can be targeted 
therapeutically to improve glucose metabolism and memory. Moreover, we believe that it is 
crucial to monitor the levels of not just cholesterol but also its counterpart 27-OH.  
The current concepts that we portray within this thesis may be out of bounds of the current 
rhetoric for the development of diseases such as Alzheimer’s disease. However, we believe that it 
is essential to tread into new areas and create new threads of thought that connects the many 
factors that together, cause these diseases. Diseases that affect millions worldwide, crippling not 
only their lives but the lives of the many people that they touch with their hearts. In an attempt 
to provide them with hope that their future is not futile. That they can take solace in knowing 
that we and others are working hard to understand and help prevent the shadow that is taking a 
hold of their minds.  
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Professor Bengt Winblad, your contribution to science at large and Alzheimer’s disease in 
particular is extremely admirable. The many networks, institutions and centers you have created 
are proof in your ability in recruiting fine talents and your resourcefulness. Leading by example 
and motivating the people around you, to not only give their best but to be the best. Surrounding 
yourself with competent and enthusiastic individuals such as Gunilla Johansson, who I would 
also like to acknowledge for her hard and dedicated work.  She managed to create an atmosphere 
that is conducive for both research and fun, which are noticeable in all the meetings she 
organized such as the Swedish Brain Power and StratNeuro. Gunilla, your proficient signature in 
everything you do is warmly felt and highly appreciated.  
I also would like to take this opportunity to thank Professor Agneta Mode and Lektor Lars-
Arne Haldosen. You have welcomed us during the master program with such grace and open 
arms. You also kept an open mind and listened to our concerns in improving the program, two 
qualities essential in your quest in making the program better and of a high caliber. Your 
guidance and suggestions helped all of us achieve and make good choices in our careers, that you 
still follow proudly, knowing that you had a part in our success.  
Professor Maria Eriksdotter, the head of the NVS department, for your enthusiasm to new 
ideas and the constant drive towards making the department the most outstanding in KI. Your 
encouragement and support of the student-led activities will undeniably create a more interactive 
and collaborative environment not only for the students but everyone at NVS. I also appreciate 
the work that the team, you chose to have by your side, performs represented by Ulla Cronfalk-
Hernlund, Asnate Maddalo and Caroline Kåhre.  
The Forskarutbildningskommitté, headed by Senior Lecturer Maria Ankarcrona, for the 
massive efforts that you have given in developing and raising the quality of doctoral education 
within the department. Becoming a role model in the process that other departments look up to 
and hope to attain. Your keen ability to see where we can improve and attentiveness and 
flexibility to the solution wherever it may lay are surely indispensible to your progress. Annette 
Karlsson, you were definitely an essential asset to the department. You always had the interest of 
the doctoral students in mind and worked hard in influencing their lives in a positive note. Your 
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creativity and eagerness to learn new things shined brightly when solving the many problems that 
arose and making it look easy. The optimism you displayed was always reassuring and I can only 
say that it was a pleasure working with you and wish you more successes to come your way. 
Selma Wolofsky, you arrived during the end of my term as chair of the doctoral council, though 
you still managed to make an everlasting impression. Your enthusiasm and dedication towards 
your work was evident from the start. You, dare I say, revolutionized public relations at the 
department, creating a platform for everyone to share their accomplishments and mainstreaming 
it. Making the department more visible within KI and I’m positive that you will achieve many 
great things in the arena of publicizing science.  
All my co-authors and collaborators especially Lars-Olof Wahlund and Eric Westman, you 
both were instrumental in finalizing the third paper. Eric your push to get things done and 
quickly was greatly appreciated. I also want to thank you for all the laughs we had over the years, 
it truly made it fun to come to work. I wish you all the success in the future. Irina Savitcheva 
for your assistance in spite having no time, and always being very supportive. Both Maura 
Heverin and Zeina Ali who without their essential contribution there would be no animals to 
investigate our ideas on. And last but not least Rebecca Schüle, Ludger Schöls, Valerio 
Leoni, Eran Leitersdorf and Balázs Gulyás.  
The researchers that make up our small scientific community, together you have contributed to 
the environment that incubates us. Each with your own set of research skills and perspectives 
forming a complementary and strong foundation for the Center for Alzheimer research. Nenad 
Bogdanovic for your encouragement, support and creating the bridge for me to pursue my next 
challenge, the clinic. Miia Kivipelto for your constructive suggestions and confidence in the 
science we do. Furthermore, for advocating that Alzheimer’s disease is much more than just 
amyloid beta and tau tangles and allowing us to collaborate to advance this new conception. 
Marianne Schultzberg for your aspiration in achieving better education previously as our 
department’s Director of doctoral education and now as Dean of doctoral education. It is always 
charming to chat with you and get your perspective on the many happenings in KI. I wish you 
the best in your new appointment. Helena Karlström for always being helpful and welcoming 
even when you’re busy. Lars Tjernberg for your motivational and instructive exercise advice. 
And cracking out jokes when I least expected it. Homira Behbahani for organizing the PhD 
seminar and making us realize how important it is for us. I also appreciate all your work and 
effort in creating a more equal and less discriminative environment and your support for our 
student activities. Gabriella Spulber for always lending a listening ear and offering great advice. 
I also appreciate the competitiveness you have, revealing it during our soup battle several years 
back. Abdul H. Mohammed for the interesting stories that you shared with me. Annica 
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